SLC67A1 and lung adenocarcinoma: For lung adenocarcinoma patients, we found that a higher expression of SLC22A18 and SLC22A18AS was significantly associated with worsening disease progression (hazard ratio (HR) = 1.51, 95% confidence interval (CI) = 1.09–2.08, p = 0.011; and HR = 2.43, 95% CI = 1.77–3.34, p < 0.001, respectively).